PHO-COG-CROOP-ADVL1312; A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children Adolescents and Young Adults With Relapsed or Refractory Solid Tumors
This phase I/II trial studies the side effects and best dose of WEE1 inhibitor MK-1775 and irinotecan hydrochloride in treating younger patients with solid tumors that have come back or that have not responded to standard therapy. WEE1 inhibitor MK-1775 and irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
The purpose of this study us to estimate the maximum tolerated dose (MTD) and/or recommended Phase 2 dose of MK-1775 (WEE1 inhibitor MK-1775) administered on days 1 through 5 every 21 days, in combination with oral irinotecan (irinotecan hydrochloride), to children with recurrent or refractory solid tumors; to define and describe the toxicities of MK-1775 in combination with oral irinotecan administered on this schedule; and to characterize the pharmacokinetics of MK-1775 in children with refractory cancer.
- IRB Number: 1404716151
- Research Study Identifier: TX4083
- Principal Investigator: James Croop, MD, PhD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required